Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
2014
B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response
2011
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
2010 Standout
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
2014
The “cancer immunogram”
2016 Science
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1–PD-L1 pathway
2006
The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response
2009 StandoutNobel
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
2009 StandoutNobel
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
2009
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
2013
Engineering precision nanoparticles for drug delivery
2020 Standout
High-intensity focused ultrasound in the treatment of solid tumours
2005
PD-1 and its ligands in T-cell immunity
2007
New Technology and Health Care Costs — The Case of Robot-Assisted Surgery
2010 Standout
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
2007
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer
2008
Fluorescence Imaging in Surgery
2013 Nobel
Clinical and future applications of high intensity focused ultrasound in cancer
2011
Fatal Autoimmune Hepatitis Induced by Concurrent Loss of Naturally Arising Regulatory T Cells and PD-1-Mediated Signaling
2008 StandoutNobel
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
2013
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study
2017 Standout
PDL1 Regulation by p53 via miR-34
2015
Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs
2007
Nasopharyngeal carcinoma
2019 Standout
Suppressive effects of tumor cell-derived 5′-deoxy-5′-methylthioadenosine on human T cells
2016
Clinical‐Pathologic Correlation Between Transperineal Mapping Biopsies of the Prostate and Three‐Dimensional Reconstruction of Prostatectomy Specimens
2012
Delivery technologies for cancer immunotherapy
2019 Standout
The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer
2007
Renal sympathetic nerve activity modulates afferent renal nerve activity by PGE2-dependent activation of α1- and α2-adrenoceptors on renal sensory nerve fibers
2007
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Inhibitory B7-family molecules in the tumour microenvironment
2008
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Healing sound: the use of ultrasound in drug delivery and other therapeutic applications
2005
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
2013
Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review
2014
Bladder cancer
2016 Standout
Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer
2016
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Role of Diffusion-Weighted Magnetic Resonance Imaging in Predicting Sensitivity to Chemoradiotherapy in Muscle-Invasive Bladder Cancer
2012
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro
2008
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
2009 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
2010 StandoutNobel
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
2006
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
2008 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway
2008 StandoutNobel
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
2010 Standout
Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
2016 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Bladder Cancer
2020 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
2009
Materials Chemistry of Nanoultrasonic Biomedicine
2016
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
2008
Prospective Validation of the Clinical Usefulness of Reflex Fluorescence In Situ Hybridization Assay in Patients With Atypical Cytology for the Detection of Urothelial Carcinoma of the Bladder
2009
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
PD-1 deficiency reveals various tissue-specific autoimmunity by H-2band dose-dependent requirement of H-2g7for diabetes in NOD mice
2008 StandoutNobel
Nanoscale theranostics for physical stimulus-responsive cancer therapies
2015
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
2007 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression
2013
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
2010 Standout
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Overall survival and PD‐L1 expression in metastasized malignant melanoma
2010
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
2014 Standout
Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy
2016 Standout
Tissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
2011 StandoutNobel
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
2007
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Absorption by water increases fluorescence image contrast of biological tissue in the shortwave infrared
2018 StandoutNobel
Metronomic chemotherapy and immunotherapy in cancer treatment
2017
Works of Bernhard Walter being referenced
PSA Nadir Is a Significant Predictor of Treatment Failure after High-Intensity Focussed Ultrasound (HIFU) Treatment of Localised Prostate Cancer
2007
Morbidity associated with repeated transrectal high-intensity focused ultrasound treatment of localized prostate cancer
2006
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
2006
High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience
2004
First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer
2007
Clinically Relevant Reduction in Risk of Recurrence of Superficial Bladder Cancer Using 5-Aminolevulinic Acid-Induced Fluorescence Diagnosis: 8-Year Results of Prospective Randomized Study
2007
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial
2011
Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor
2010
SYSTEMIC AND TOPICAL DRUG ADMINISTRATION IN THE PIG URETER: EFFECT OF PHOSPHODIESTERASE INHIBITORS α1, β AND β2-ADRENERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE FREQUENCY AND AMPLITUDE OF URETERAL CONTRACTIONS
2001
15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.
2011